SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

@article{Zelniker2019SGLT2IF,
  title={SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials},
  author={Thomas A. Zelniker and Stephen D. Wiviott and Itamar Raz and Kyungah Im and Erica L. Goodrich and Marc P. Bonaca and Ofri Mosenzon and Eri Toda Kato and Avivit Cahn and Remo H M Furtado and Deepak L. Bhatt and Lawrence A Leiter and Darren K Mcguire and John P H Wilding and Marc S. Sabatine},
  journal={The Lancet},
  year={2019},
  volume={393},
  pages={31-39}
}
BACKGROUND The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based on key baseline characteristics remains undefined. METHODS We did a systematic review and meta-analysis of randomised, placebo-controlled, cardiovascular outcome trials of SGLT2i in patients with type 2 diabetes. We searched PubMed and Embase for trials published up to Sept 24, 2018. Data search and extraction were completed… Expand

Paper Mentions

Interventional Clinical Trial
Type 2 diabetes mellitus (T2DM) is an independent risk factor for heart failure (HF) and is associated with significant morbidity and mortality. Recent therapeutic advances in… Expand
ConditionsDiabetes Mellitus, Type 2, Heart Failure
InterventionBehavioral
News Article
Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
TLDR
Compared with placebo, SGLT-2 inhibitors have remarkable cardiovascular benefits in a broad range of HF patients and Beneficial effects were robust in HF patients regardless of T2DM status, and a strong trend to be effective in HFpEF. Expand
Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
TLDR
A systematic review and meta-analysis revealed that SGLT-2i treatment significantly reduced all-cause mortality, cardiovascular mortality, and hospitalisation for heart failure (HHF) in patients with cardiovascular disease and induced a lower incidence of renal damage and myocardial infarction than the placebo group. Expand
Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
TLDR
In patients with cardiometabolic and kidney disease, SGLT2i improved cardiovascular and kidney outcomes, regardless of T2DM, HF, and/or CKD status. Expand
SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies.
To investigate whether sodium glucose cotransporter 2 inhibitors (SGLT2is) can reduce important cardiorenal endpoints in type 2 diabetic adults without established cardiovascular disease (ECD), inExpand
Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes
TLDR
Trial sequential analyses for MI and stroke showed that cumulative Z curve did not cross trial sequential monitoring boundary and required information size, whereas those for the other 6 endpoints showed that Cumulative Z curve crossed trial sequential Monitoring boundary and/or required information sizes. Expand
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
TLDR
Evidence is provided that the proportional effect of SGLT2 inhibitors might attenuate with declining kidney function and there was clear, separate evidence of benefit for all eG FR subgroups, including for participants with a baseline eGFR 30-45 mL/min per 1·73 m2. Expand
The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis
TLDR
SGLT2i are associated with significantly lower major adverse cardiovascular events, heart failure hospitalizations, and all-cause mortality, and the evidence is strongest in reducing heart failureospitalizations. Expand
Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
  • L. Tian, Yuzi Cai, +6 authors Yaoxian Wang
  • Medicine
  • Frontiers in Pharmacology
  • 2021
TLDR
This meta-analysis suggests that canagliflozin protects against cardiovascular and renal outcomes in patients with T2DM. Expand
Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators
TLDR
Empagliflozin is the best treatment option among SGLT2i for this type of patient, but the evidence is not consistent enough, and in patients with T2DM at cardiovascular risk, ertugliflozar is a less potent drug than empag liflozin, canaglif Lozin or dapaglif lozin to prevent cardiorenal events and all-cause mortality. Expand
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
TLDR
A meta-analysis of 6 randomized, placebo-controlled CV and kidney outcomes trials of SGLT2 inhibitors in patients with type 2 diabetes found that SGLt2 inhibitors were associated with a reduced risk of major adverse CV events. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
TLDR
Available data suggest that the beneficial action observed with empagliflozin on all-cause and cardiovascular mortality in EMPAREG OUTCOME study is a class effect. Expand
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review.
TLDR
Known and possible mechanisms that contribute to the salutary effects of SGLT2is are summarized and the interplay between cardiac and renal function, as well as safety issues associated with this class of drugs are discussed. Expand
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
TLDR
The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. Expand
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
TLDR
In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in anLower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rates of hospitalizationFor heart failure. Expand
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
TLDR
Canagliflozin treatment was associated with a reduced risk of sustained loss of kidney function, attenuated eGFR decline, and a reduction in albuminuria in patients with type 2 diabetes. Expand
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
TLDR
In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care. Expand
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
TLDR
In patients with type 2 diabetes and high cardiovascular risk, empagliflozin reduced heart failure hospitalization and cardiovascular death, with a consistent benefit in patients with and without baseline heart failure. Expand
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
TLDR
Empagliflozin improved clinical outcomes and reduced mortality in vulnerable patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Expand
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry
Background— Despite the known association of diabetes mellitus with cardiovascular events, there are few contemporary data on the long-term outcomes from international cohorts of patients withExpand
...
1
2
3
4
5
...